Antitumor effects of low-dose metronomic cyclophosphamide combined with Herceptin in orthotopic erbB2-overexpressing mammary tumors.

被引：0
|
作者：
Du Manoir, JM [1 ]
Viloria-Petit, A [1 ]
Man, S [1 ]
Mossoba, M [1 ]
Medin, JA [1 ]
Kerbel, RS [1 ]
机构：
[1] Univ Toronto, Dept Med Biophys, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6149S / 6149S
页数：1
相关论文
共 50 条
  • [31] In Utero Exposure to Low-Dose Alcohol Induces Reprogramming of Mammary Development and Tumor Risk in MMTV-erbB-2 Transgenic Mice
    Ma, Zhikun
    Blackwelder, Amanda J.
    Lee, Harry
    Zhao, Ming
    Yang, Xiaohe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (04) : 7655 - 7671
  • [32] Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
    Nijhof, Inger S.
    Franssen, Laurens E.
    Levin, Mark-David
    Bos, Gerard M. J.
    Broijl, Annemiek
    Klein, Saskia K.
    Koene, Harry R.
    Bloem, Andries C.
    Beeker, Aart
    Faber, Laura M.
    van der Spek, Ellen
    Ypma, Paula F.
    Raymakers, Reinier
    van Spronsen, Dick-Johan
    Westerweel, Peter E.
    Oostvogels, Rimke
    van Velzen, Jeroen
    van Kessel, Berris
    Mutis, Tuna
    Sonneveld, Pieter
    Zweegman, Sonja
    Lokhorst, Henk M.
    van de Donk, Niels W. C. J.
    BLOOD, 2016, 128 (19) : 2297 - 2306
  • [33] THERAPY OF MURINE TUMORS WITH HIGH-DOSE INTERLEUKIN-2 (IL2) AND CYCLOPHOSPHAMIDE (CY) MECHANISMS OF THE ENHANCED ANTITUMOR EFFECTS
    YANG, JC
    PRATS, I
    PAPA, MZ
    ROSENBERG, SA
    FEDERATION PROCEEDINGS, 1987, 46 (04) : 1509 - 1509
  • [34] Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
    Sophie Cousin
    Maud Toulmonde
    Michèle Kind
    Jean-Philippe Guegan
    Alban Bessede
    Coralie Cantarel
    Carine Bellera
    Antoine Italiano
    Experimental Hematology & Oncology, 11
  • [35] Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
    Cousin, Sophie
    Toulmonde, Maud
    Kind, Michele
    Guegan, Jean-Philippe
    Bessede, Alban
    Cantarel, Coralie
    Bellera, Carine
    Italiano, Antoine
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [36] Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration - Antitumor activity and immunomodulatory effects
    Tagliaferri, P
    Barile, C
    Caraglia, M
    Guarrasi, R
    Morelli, D
    Ricciardi, B
    Martignetti, A
    Librera, MT
    Matano, E
    Della Vecchia, A
    Catalano, G
    Famiani, M
    Palmieri, G
    Correale, P
    Bianco, AR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (01): : 48 - 53
  • [37] Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): A phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination
    Fontana, A.
    Bocci, G.
    Galli, L.
    Fontana, E.
    Antonuzzo, A.
    Galli, C.
    Loupakis, F.
    Allegrini, G.
    Di Marsico, R.
    Landi, L.
    LoDico, M.
    Mazzoni, E.
    Safina, V
    Barletta, M.
    Andreuccetti, M.
    Barsanti, G.
    Fioravanti, A.
    Orlandi, P.
    Del Tacca, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI79 - XI79
  • [38] Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): A phase ii clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination
    Fontana, Andrea
    Bocci, Guido
    Fontana, Eloise
    Galli, Costanza
    Loupakis, Fotios
    Landi, Lorenza
    Lo Dico, Monica
    Mazzoni, Enrica
    Barsanti, Gemma
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2006, 17 : 150 - 150
  • [39] A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)
    De Tursi, M.
    Carella, C.
    Ricevuto, E.
    Gennari, A.
    Orlandini, C.
    Frassoldati, A.
    Conte, P. F.
    Iacobelli, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide
    Klasa, RJ
    Bally, MB
    Ng, R
    Goldie, JH
    Gascoyne, RD
    Wong, FMP
    CLINICAL CANCER RESEARCH, 2000, 6 (06) : 2492 - 2500
12345